Amgen and Harvard Pilgrim Healthcare have entered an outcomes-based contract that is based on the efficacy of Amgen’s immunomodulatory agent etanercept (Enbrel), for patients with rheumatoid arthritis.
Amgen and Harvard Pilgrim Healthcare have entered an outcomes-based contract that is based on the efficacy of Amgen’s immunomodulatory agent etanercept (Enbrel), for patients with rheumatoid arthritis.
In a press release Harvard Pilgrim said that the 2-year contract will score patients taking etanercept based on 6 criteria, including:
Patients scores that do not meet a predetermined threshold—meaning the treatment does not present the desired “value” and real-world effectiveness—will result in lower reimbursement for Amgen.
Etanercept, a monoclonal antibody that blocks the tumor necrosis factor receptor, acts on the immune system and is indicated in the treatment of moderate to severe rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and chronic moderate to severe plaque psoriasis.
“Real-world performance of new medicines frequently differs from the well-controlled clinical trial setting,” Harvard Pilgrim Chief Medical Officer Michael Sherman, MD, said in a statement. Sherman pointed out that only about 33% of patients on etanercept and other drugs in the same class meet all 6 criteria. “By linking the ultimate cost of this drug to its real-world clinical efficacy, this agreement truly puts patients at the center of focus,” he added.
Amgen’s strategy to sign this value-based contract might have been influenced by the approval of its biosimilar competition, etanercept-szzs (Erelzi), developed by Sandoz. While a patent-related litigation between Amgen and Sandoz has pushed the biosimilar launch to 2018, Erelzi could potentially divert a significant portion of the originator product’s market share. The 2 companies are also locked in another case, which will be heard by the Supreme Court, over when a 6-monthh waiting period begins for a biosimilar developer who has informed the developer of the reference product about its drug.
Amgen is not a new entrant to the world of outcomes-based contracts—the company negotiated a similar deal with Harvard Pilgrim in 2015 for its anticholesterol agent Repatha, a PCSK9 inhibitor.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More